WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) is set to host a virtual Investor Day Presentation on October 1 at 3 pm ET, where it will unveil promising new results from its Phase 2b SEISMiC Extension Study of istaroxime, a pioneering treatment for early cardiogenic shock. This event will also outline the company’s forward-looking strategies and upcoming milestones.
The Investor Day will spotlight istaroxime, a novel therapy aimed at enhancing heart function by improving systolic contraction and diastolic relaxation, while simultaneously elevating blood pressure and supporting renal performance. The drug has already shown positive outcomes across four Phase 2 trials involving patients with acute heart failure and early cardiogenic shock, conditions marked by dangerously low blood pressure and impaired blood flow to critical organs.
Joining Windtree’s management team is Alexandre Mebazaa, MD, PhD, a renowned cardiogenic shock and heart failure expert from Hospital Lariboisière in Paris. His insights will provide depth to the discussion on the potential impact of istaroxime in treating early cardiogenic shock, a critical condition requiring innovative solutions.
The presentation will be conducted via Zoom, allowing investors to engage directly with the team and Dr. Mebazaa during a dedicated Q&A session. This event marks a significant milestone in Windtree’s mission to advance heart failure treatments and offers an opportunity for investors to understand the future direction of the company. Registration is required.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.